[Market Focus] Samchundang Pharm Surges Over 10% on Eylea Biosimilar Export News

Samchundang Pharm is experiencing a sharp rise following news of exports of its biosimilar for the ophthalmic disease treatment 'Eylea.'

As of 9:39 a.m. on June 5, Samchundang Pharm was trading at 159,900 won on the Korea Exchange, up 14,700 won (10.12%) from the previous day.

On this day, Samchundang Pharm announced that the first commercial shipment of its Eylea biosimilar had been shipped and that sales in the relevant country would begin in July.